A patient with osteoporosis begins denosumab therapy. Which pathway is targeted?
Show answer and explanation
Correct answer: RANKL inhibition
Denosumab is a monoclonal antibody against RANKL, preventing osteoclast activation. It reduces bone resorption.
Practice all 20 Musculoskeletal and Skin: Osteoporosis, Psoriasis questions
Keep practicing
More Musculoskeletal and Skin: Osteoporosis, Psoriasis questions
- Which of the following nail findings is MOST specific for psoriasis?
- A 60-year-old woman develops vertebral fractures despite adequate calcium intake. Her labs show low vitamin D levels. What is the mechanism?
- A biopsy of a psoriatic plaque shows parakeratosis. What does this indicate?
- Which comorbidity is strongly associated with psoriasis due to chronic systemic inflammation?
- A patient with osteoporosis sustains a Colles fracture. This involves which bone?
- A 72-year-old woman presents with a hip fracture after a minor fall. DEXA scan shows a T-score of –2.8. Which pathophysiologic process is m…